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Abstract
Background: Failed hip prostheses can cause elevated circulating cobalt and chromium levels, with rare reports of
fatal systemic organ deposition, including cobalt cardiomyopathy. Although blood cobalt and chromium levels are
easily measured, organ deposition is difficult to detect without invasive biopsy. The T2* magnetic resonance (MR)
method is used to quantify tissue iron deposition, and plays an important role in the management of iron-loading
conditions. Cobalt and chromium, like iron, also affect magnetism and are proposed MR contrast agents.
Case Presentation: We describe a case of a 44-year-old male with a failed hip implant and very elevated blood
cobalt and chromium levels. Despite normal cardiac MR findings, liver T2* and R2 values were abnormal, triggering
tissue biopsy. Liver tissue analysis, including X-ray fluorescence, demonstrated heavy elemental cobalt and
chromium deposition in macrophages, and no detectable iron.
Conclusions: Our case demonstrates T2* and R2 quantification of liver metal deposition in a patient with a failed
hip implant. Further work is needed to investigate the role of T2* and R2 MR in the detection of metal deposition
from metal on metal hip prostheses.
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Background
Hip replacement surgery is highly successful and
300,000 procedures are performed per year in the US
alone. Sometimes they fail early. Recently a new mech-
anism and consequence of failure has been identified:
the release of metal debris. This is common in patients
with metal-on-metal (MoM) hip implants, but may
occur in other implant types when ceramic/plastic com-
ponents fracture.
The metal alloys used in hip implants are safe when the
bulk material is considered. However, wear and corrosion
of these alloys may result in the generation of metal nano-
particles and metal ions with the most clinically relevant
metal elements being cobalt (Co) and chromium (Cr) in
both physical forms. Metal ion release can cause local soft
tissue reactions and systemic toxicity, with reports of fatal
cobalt cardiomyopathy, thyroid, and neuro-ocular toxicity
[1, 2]. Although the causative mechanisms remain unclear,
component design, positioning, female gender, and the
hypoxia-inducible factor pathway are linked to complica-
tions [3–6].
Serial measurement of serum metal ion levels in symp-
tomatic patients with MoM hips is currently recom-
mended by the medical device regulatory bodies
(including the FDA and MHRA), and guides manage-
ment including revision [2, 7]. A threshold of 7 mcg/L
(118 nmol/L cobalt or 134.5 nmol/L chromium) tracks
risk of local soft tissue reactions and risk of failed resur-
facings/total hip arthroplasties, but there are currently
no non-invasive tests for the detection of systemic or
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organ - specific toxicity. Confirmation of systemic tox-
icity has previously been from invasive tissue biopsy or
post-mortem studies.
Magnetic resonance (MR) imaging using the T2* or R2
technique is the current gold-standard method for de-
tection and quantification of iron deposition in patients
with iron overload, and has histological validation [8, 9].
In such patients, the liver is the dominant site of iron
storage and liver iron levels reflect total body iron stores
and predict outcomes including liver and heart failure
[10]. Iron exhibits ferromagnetic properties and acts like
a contrast agent, relaxing water hydrogen, which is de-
tectable as an MR signal. Both cobalt and chromium
have magnetic properties and have been proposed as
MR contrast agents [11, 12] and should therefore be de-
tectable in vivo using MR T2* quantification. Cobalt like
iron is ferromagnetic, and chromium is diamagnetic or
paramagnetic depending on the oxidation state and this
has a direct effect on magnetic susceptibility. We de-
scribe a patient with a failed hip implant where MR ab-
normalities raised the suspicion of remote organ (liver)
involvement, with subsequent confirmation of high level
tissue Co and Cr deposition on biopsy.
Case presentation
A 44-year-old man presented to our institution with hip
pain, a peri-prosthetic mass and scar pigmentation. He had
initially undergone primary total hip arthroplasty 35 months
previously, with a ceramic on ceramic bearing for osteo-
arthritis. 16 months following implantation, this was revised
to a metal on polyethylene bearing implant, following a cer-
amic acetabular liner fracture. On presentation to our insti-
tution, laboratory investigations revealed extreme blood Co
and Cr levels (587.9 mcgg/L and 20.4 mcgg/L respectively),
with normal inflammatory markers. Urgent re-revision sur-
gery to a new ceramic on ceramic bearing hip implant was
performed. At surgery we found a catastrophically worn
metal head (made of CoCr alloy) and substantial soft tissue
metallosis. His blood ion levels reduced after re-revision
surgery but were sufficient to cause concern regarding po-
tential cobalt cardiotoxicity, and he was therefore referred
for cardiac assessment using cardiovascular MR (CMR).
Due to the nature of the referral with concerns of metal
loading, tissue characterization sequences of the liver were
also acquired.
Investigations
Blood tests
Blood Co and Cr levels were very high and fell with revi-
sion, (Table 1). All routine hematological and biochem-
ical blood tests were normal throughout the follow up
period, including liver function, enzymes, and iron stud-
ies. He was known to be hypothyroid prior to surgery,
and blood tests found him to be euthyroid on replace-
ment therapy.
Magnetic resonance Imaging Protocol
CMR was performed using a 1.5 Tesla Magnetic Reson-
ance scanner (Avanto, Siemens medical solutions, Er-
langen, Germany). Cardiac volumes and function were
calculated from short-axis steady state free precession
(SSFP) cine images. Pre-contrast myocardial and liver
T2* maps were acquired using a single breath-hold
ECG-gated multi-echo technique to generate eight
(heart) and twelve (liver) images (TR: 2 msec, TE 2.59-
18.2 cardiac and minimum TE 0.99 ms liver, slice thick-
ness: 10 mm, flip angle: 20°, field of view read/ phase:
400 mm/75 %). In addition, a T2 (presented as recipro-
cal, R2) measurement (FerriScan®) was performed
through the middle of the liver in the transverse plane
[13]. Late gadolinium enhancement images were ac-
quired after administering 0.1 mmol/kg of gadolinium-
based contrast (gadoterate meglumine - Dotarem, Guer-
bet SA, Paris, France). Following the initial study,
6 weeks post-surgery, four identical but non-contrast
serial scans were performed within a fourteen-month
period (Table 1).
MR results
Cardiac volumetric and functional assessments were
normal in all studies, with normal myocardial T2* values
when compared with published values (Table 1) [14, 15].
The liver was found to have shortened signal decay by
Table 1 Serial blood cobalt and chromium levels with concurrent myocardial and hepatic T2*
Scan Date
(month/year)
LVEF
(%)
EDV
(ml)
ESV
(ml)
Mass
(g)
Cardiac T2* (ms)
(LLN 20 ms)
Liver T2* (ms)
(LLN 6.3 ms)
Equivalent liver iron
concentration using
FerriScan R2 (mg/g/dry tissue)
Blood Co
(ULN 0.9mcg/L)
Blood Cr
(ULN <0.3mcg/L)
1 Apr-14 68 142 46 127 29 4.2 3.9 9976 393
2 Oct-14 66 139 47 122 24 3.3 5.6 392 200
3 Jan-15 60 143 58 129 36 3 5.3 276 192
4 Jun-15 65 145 51 113 27 2.9 5.3 151 132
Myocardial T2* values were normal. Short hepatic T2* values (normal greater than 6.2 ms) indicate the presence of metal. Despite falling blood metal ion levels,
liver MR results suggested increasing tissue deposition. Ferriscan measurements demonstrate the detectable signal change and iron equivalent for an iron-loaded
patient. (LLN lower limit of normal, ULN upper limit of normal)
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T2*, and R2 values at levels usually consistent with the
equivalent of mild liver iron (Fe) overload on all scans,
Fig. 1. Despite normalizing blood Co and Cr levels over
the 16 month period post revision, the first three T2*
values suggested worsening liver involvement (Table 1).
Hemochromatosis DNA testing
Restriction enzyme PCR revealed the patient to be HFE
compound heterozygous for C282Y/H63D, known to
cause <5 % of cases of hereditary hemochromatosis.
With this mutation, iron loading is uncommon without
a second co-factor such as alcohol abuse or hepatitis
[16], and patients have abnormal iron biochemistry [17].
Combined review by hepatology and ferro-hematology
teams concluded his abnormal liver MR results were un-
likely to be caused by iron loading despite the mutation.
Liver biopsy
The patient underwent ultrasound-guided liver biopsy.
Care was taken to avoid metal contamination with Fe, Co
or Cr. Liver tissue was analyzed at 3 separate reference la-
boratories for histology, iron quantification, and Co-Cr
detection. Standard liver histology was within normal
limits and no fibrosis, no iron or copper was identified,
however apparent metal deposits were detected in liver
macrophages (Fig. 2).
To determine the exact location and chemical compos-
ition (speciation) of this, we performed micro-X-ray Fluor-
escence (μXRF) and micro X-ray Absorption Spectroscopy
(μXAS) on beamline I18 at Diamond Light Source
(Harwell, UK) [18]. μXRF elemental mapping causes
minimal sample damage, is sensitive to very low
concentrations, and allows the samples to be later
treated by conventional histology techniques for co-
registration. μXAS can then provide details on the
speciation. These showed an abundance of highly co-
localized Co and Cr metallic particulate debris in
macrophages with no isolated Cr or Co (Fig. 2). The
particles were found to have uniform composition
across samples, but an enhanced Co to Cr ratio (4.1:1)
compared to the source hip (ASTM F75 alloy typically
Co:Cr 2.25:1).
Discussion
We present the first description of the use of T2* and
R2 MR to non-invasively detect and map liver Co and
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Fig. 1 Liver T2* MR maps of patient compared with healthy volunteer. Left panel (a) shows the patient with a low T2* (final scan), compared to a
healthy volunteer shown in the right panel (b) with normal T2* values
Fig. 2 Analysis of liver biopsy tissue using micro X-ray Fluorescence (μXRF, left) found cobalt and chromium co-localised in macrophages (right).
Left: μXRF element distribution color maps with 4 μm resolution - Co (green), Cr (red) and Calcium, Ca (blue) showing deposits (white arrow). The
Ca distribution provides a background image of the tissue. Right: the same slide subsequently H&E stained showing aggregates of pigmented macro-
phages (black arrow)
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Cr. Our patient had extremely elevated blood metal
levels from a failed hip prosthesis with wear of the Co-
Cr head and the highest values seen by their attending
surgeons at a large specialist retrieval unit in London.
Liver biopsy followed by μXRF and μXAS confirmed
Co-Cr debris in liver macrophages, with no other ferro-
magnetic material deposits found. Serial assessment sug-
gested clearance from the liver was far slower than from
the blood.
More than one million people globally have MoM hip
prostheses and are “at-risk” of Co-Cr release. This causes
a high failure rate due to local soft tissue reactions caus-
ing pain and pseudotumors. The failure rate of these
hips can be up to 40 % by 7 years [19], and implantation
of these has now all but ceased. Co-Cr release may also
occur with other types of prostheses, here due to
ceramic fracture - although improved surgical technique,
implant design and materials are making this uncom-
mon. In addition to local complications, there is concern
from clinicians and patients alike regarding potential
systemic toxicity from the high blood Co and Cr. Sys-
temic organ deposition is hard to measure without inva-
sive biopsy, meaning that currently available evidence is
not always robust. This uncertainty coupled with
medico-legal influences have fuelled patient anxiety, are
driving some aspects of management, and highlight the
need for non-invasive tests for systemic organ deposition.
This case illustrates that systemic deposition of Co
and Cr in the liver can occur in subjects with extreme
blood levels of metal secondary to failed hip implants,
even without blood markers of hepatic abnormality. The
absence of liver enzyme disturbance suggests that this
patient tolerated the Co and Cr, at least in the short
term. The relationship of liver deposition/sequestration
to other organ toxicity (brain, thyroid, spleen etc.) is un-
known. In iron loading states the deposition of iron oc-
curs primarily in the liver followed by deposition in
other organs including the heart. A similar pattern may
be seen in patients with increased levels of blood Co and
Cr. The relative proportions of Co and Cr suggest
progressive particle processing during the transport from
the hip to the liver, although this mechanism remains
unknown.
T2* and R2 MR are currently routinely used to detect
and quantify iron tissue deposition in the heart and liver,
and have significantly changed disease outcomes. Iron de-
position with T2* MR of the pancreas, pituitary and kid-
neys is also potentially quantifiable. These techniques
could also be repurposed for non-invasive screening of
Co-Cr deposition in at-risk patients. To date, only non-
specific qualitative abnormalities have been reported on
CMR scans in patients with biopsy proven Co cardiomy-
opathy [20, 21]; the reported changes likely reflecting the
myocyte response and inflammation rather than
deposition. A non-invasive tool for Co/Cr organ depos-
ition, if sensitive, would likely influence clinical decision-
making. Whether the non-invasive detection as described
here works only in extreme cases, or whether liver (or
other organ) metal quantification may inform about risk
in that or other organs is unknown. Further research is
needed. A limitation of this report is that Fe, Co and Cr
levels were not quantified in the liver biopsy for compari-
son with the MR findings.
Conclusions
Over one million patients with MoM hip prostheses are at
risk of cobalt/ chromium toxicity with potentially devas-
tating complications. The T2* method plays an integral
part in the management of patients with iron overload,
and this technique may also detect CoCr deposition in the
liver as demonstrated by our case. Further work is needed
to assess the utility of T2* and R2 MR as a screening tool
in at-risk patients with MoM hip prostheses.
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